New Vaccine For Two Deadly Cancers Shows Promise in Clinical Trial

New Vaccine For Two Deadly Cancers Shows Promise in Clinical Trial

Notoriously hard to treat, pancreatic and colorectal cancers each have high recurrence rates in the years following treatment.

Off-The-Shelf Vaccine Elicits Durable Responses in Pancreatic, Colorectal Cancers

Dr. Zev Wainberg of UCLA recently spoke with CURE about trial results concerning the cancer vaccine ELI-002 2P.

Cancer Vaccine ELI-002 2P Shows Potential Survival Benefits in KRAS-Mutated Pancreatic and Colorectal Cancers

A recent study has revealed that ELI-002 2P, a cancer v […] The post Cancer Vaccine ELI-002 2P Shows Potential Survival Benefits in KRAS-Mutated Pancreatic and Colorectal Cancers first appeared on GeneOnline News. The post Cancer Vaccine ELI-002 2P Shows Potential Survival Benefits in KRAS-Mutated Pancreatic and Colorectal Cancers appeared first on GeneOnline News.

KRAS-Targeted Vaccine Shows Durable Immune Responses, Survival Benefits in Pancreatic Colorectal Cancers

Elicio Therapeutics' ELI-002 2P cancer vaccine shows promising survival benefits in pancreatic and colorectal cancer patients, enhancing immune responses.

Elicio’s peptide cancer vaccine shows survival benefit in Phase I trial

Elicio's mKRAS-targeting cancer vaccine reduced the risk of death by 77% by activating the anti-tumour mechanisms of key immune cells.The post Elicio’s peptide cancer vaccine shows survival benefit in Phase I trial appeared first on Clinical Trials Arena.